Summary

Types of mito, summary icon - DNA affected icon

Type of DNA affected

Mitochondrial or nuclear DNA

Types of mito, summary icon - Types of mito, summary icon - Genetic change icon

Common genetic change

Mitochondrial deletion

Types of mito, summary icon - Age of onset icon

Typical age of onset

Before the age of 20

Types of mito, summary icon - Body area affected

Body area impacted

Brain and muscles

Summary

Types of mito, summary icon - DNA affected icon

Type of DNA affected

Mitochondrial or nuclear DNA

Types of mito, summary icon - Types of mito, summary icon - Genetic change icon

Common genetic change

Mitochondrial deletion

Types of mito, summary icon - Age of onset icon

Typical age of onset

Before the age of 20

Types of mito, summary icon - Body area affected

Body area impacted

Brain and muscles

Summary

Types of mito, summary icon - DNA affected icon

Type of DNA affected
Mitochondrial or nuclear DNA

Types of mito, summary icon - Types of mito, summary icon - Genetic change icon

Common genetic change
Mitochondrial deletion

Types of mito, summary icon - Age of onset icon

Age of onset
Before the age of 20

Types of mito, summary icon - Body area affected

Body area impacted
Brain and muscles

Prefer to listen?

Hear this information on our Audio Learning Channel.

About KSS

Kearns–Sayre syndrome, commonly known as KSS, is a rare inherited genetic condition. It is one of at least 350 known types of mitochondrial disease (mito).

Mito affects the mitochondria, which are tiny parts inside our cells that help make the energy our bodies need. When mitochondria do not work as they should, some parts of the body may not have enough energy, like your muscles or brain, to work the way they should. In people with KSS, the brain, nervous system, and muscles are commonly affected.

When do symptoms appear?

KSS usually start before the age of 20 years old.1 Symptoms include:

  • weakness of the eye muscles (ophthalmoplegia)
  • drooping eyelids (ptosis)
  • abnormal pigmentation inside the eye (pigmentary retinopathy)
  • heart problems like cardiomyopathy and heart rhythm changes (arrhythmia).1

KSS often includes Chronic Progressive External Ophthalmoplegia (CPEO) but with signs and symptoms beyond those seen in CPEO.

Curious about mito?

For more information visit our understanding mito page. You’ll find explanations about what mito is, its symptoms, its causes, and how it affects the body.

Speech bubble icon

Pronunciation

Kearns–Say-re syndrome

KSS (KSS)

Clipboard icon

Other names for KSS.

  • Kearns-Sayre mitochondrial cytopathy
  • Chronic progressive external ophthalmoplegia and myopathy
  • Chronic progressive external ophthalmoplegia with ragged red fibres
  • CPEO with myopathy
  • CPEO with ragged red fibres
  • Mitochondrial cytopathy
  • Ophthalmoplegia, pigmentary degeneration of the retina and cardiomyopathy
  • Ophthalmoplegia plus syndrome
  • Single large-scale mitochondrial DNA deletion syndrome (SLSMDS)

KSS may also be referred to as:

  • Mitochondrial disease
  • Primary Mitochondrial Disease (PMD)
  • Mitochondrial encephalomyopathy
Emergency ambulance icon

Planning for urgent care

If your mito specialist thinks you may get unwell quickly, they may give you an emergency plan. If you do not have a mito specialist, you could ask the specialist you see who knows about mito.

An emergency plan lists your diagnosis and care information from your care team. It can help to keep a copy with you. This could be on paper, on your phone or saved where you or your carer can find it fast. You can show the plan if you go to hospital, need an ambulance or see a new health professional. It can also help to keep current contact details for your main care team. This may include your general practitioner (GP), mito specialist or other specialist. You can also list other health professionals who know you well.

The Australian Patient Care Standards for mito and Important information about medicines can also help guide health professionals who are less familiar with mito.

Icon of 3 people

Hi. I'm Victor.

Victor, 22, lives in Bulgaria and lives boldly with Kearns-Sayre syndrome. Diagnosed at 14, he faces each day with determination and a sharp sense of humour. Whether he's doing physio five times a week, swimming on weekends, or sticking to his treatment routine, Victor gives it his all, because he believes in his future.

Beyond the basics

Learn more and find support to help you navigate your journey with mito.

Flag Icon Milestones

  • Before 1958: Doctors observed individuals with progressive eye muscle weakness and other symptoms but did not yet recognise KSS as a condition.
  • 1958: Neurologists Thomas Kearns and George Sayre first described KSS as a unique disorder after studying people with eye muscle weakness, heart problems, and abnormal retinal pigmentation inside the eye.2
  • 1980s: As genetic testing advanced, scientists identified that KSS is caused by deletions (missing pieces) in mitochondrial DNA (mtDNA), confirming it as a mitochondrial disorder.3
  • From the 2000s to now: researchers continue to study new treatments, including gene therapy and mitochondrial replacement techniques, to better manage or possibly prevent KSS symptoms in the future.
Globe Icon Prevalence
Symptoms Icon Symptoms
Flag Icon Causes
Diagnosis Icon Diagnosis
Care team Icon Care team
Health care Icon Health care
Clinical studies Icon Clinical studies

Mito Foundation support services

Helpline

Call Helpine for general advice, assistance in seeking a referral or more information on Mito Foundation support services.

Events

Mito Foundation events bring together people impacted by mitochondrial disease (mito).

NDIS support

Access the NDIS Navigation Service (NNS) for resources, education and 1:1 guidance on the NDIS.

Disclaimer: Resources provided by the Australian Mitochondrial Disease Foundation Limited (Mito Foundation), offers general information and is not a substitute for medical advice. It is essential to assess the suitability of the content for your individual circumstances and make decisions based on your medical condition. The information’s accuracy is subject to change, and we do not guarantee ongoing currency or availability. While efforts are made to ensure accuracy, Mito Foundation is not obligated to provide updated information. The copyright for this document and its content belongs to, or is licensed to, Mito Foundation, and reproduction without prior written consent is prohibited.

Acknowledgement: Mito Foundation acknowledges the valuable contributions of our reviewers, we thank Professor Clare Fraser, Ophthalmologist, MBBS FRANZCO and Dr Isabel Lopez Sanchez, Research Manager, for their review. As well as Diane and Pam, members of the Mito Community Resource Review Panel.

Author: Mito Foundation 
Version: 1
Date published: Monday 16 June 2025